Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Kivistö KT[au]:

Pharmacokinetic interactions with rifampicin : clinical relevance. Niemi M et al. Clin Pharmacokinet. (2003)

Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin. Lilja JJ et al. Clin Pharmacol Ther. (2000)

Effects of milk and food on the absorption of enoxacin. Lehto P et al. Br J Clin Pharmacol. (1995)

Search results

Items: 1 to 50 of 138

1.

Possible hepatotoxic effect of rooibos tea: a case report.

Sinisalo M, Enkovaara AL, Kivistö KT.

Eur J Clin Pharmacol. 2010 Apr;66(4):427-8. doi: 10.1007/s00228-009-0776-7. No abstract available.

PMID:
20072844
2.

Propafenone for the prevention of atrial tachyarrhythmias after cardiac surgery: a randomized, double-blind placebo-controlled trial.

Mörike K, Kivistö KT, Schaeffeler E, Jägle C, Igel S, Drescher S, Fux R, Marx C, Hofmann U, Engel C, Wagner F, Delabar U, Meisner C, Bail D, Böhm JO, Gleiter CH, Ziemer G, Rein JG, Hellberg KD, Eichelbaum M, Schwab M.

Clin Pharmacol Ther. 2008 Jul;84(1):104-10. doi: 10.1038/sj.clpt.6100473. Epub 2008 Jan 2.

PMID:
18167502
3.

Mitochondrial DNA polymerase gamma variants in idiopathic sporadic Parkinson disease.

Luoma PT, Eerola J, Ahola S, Hakonen AH, Hellström O, Kivistö KT, Tienari PJ, Suomalainen A.

Neurology. 2007 Sep 11;69(11):1152-9.

PMID:
17846414
4.

Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans.

Kivistö KT, Niemi M.

Pharm Res. 2007 Feb;24(2):239-47. Epub 2006 Dec 20. Review.

PMID:
17177112
5.

Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics.

Niemi M, Arnold KA, Backman JT, Pasanen MK, Gödtel-Armbrust U, Wojnowski L, Zanger UM, Neuvonen PJ, Eichelbaum M, Kivistö KT, Lang T.

Pharmacogenet Genomics. 2006 Nov;16(11):801-8.

PMID:
17047488
6.

Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin.

Niemi M, Kivistö KT, Diczfalusy U, Bodin K, Bertilsson L, Fromm MF, Eichelbaum M.

Pharmacogenet Genomics. 2006 Aug;16(8):565-8.

PMID:
16847425
7.

Cardiovascular effects of (R)- and (S)-verapamil and racemic verapamil in humans: a placebo-controlled study.

Busse D, Templin S, Mikus G, Schwab M, Hofmann U, Eichelbaum M, Kivistö KT.

Eur J Clin Pharmacol. 2006 Aug;62(8):613-9. Epub 2006 Jul 4.

PMID:
16823584
8.
9.

Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin.

Igel M, Arnold KA, Niemi M, Hofmann U, Schwab M, Lütjohann D, von Bergmann K, Eichelbaum M, Kivistö KT.

Clin Pharmacol Ther. 2006 May;79(5):419-26. Epub 2006 Apr 11.

PMID:
16678544
10.
11.

Muscle symptoms associated with statins: a series of twenty patients.

Soininen K, Niemi M, Kilkki E, Strandberg T, Kivistö KT.

Basic Clin Pharmacol Toxicol. 2006 Jan;98(1):51-4.

12.

Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study.

Fux R, Mörike K, Pröhmer AM, Delabar U, Schwab M, Schaeffeler E, Lorenz G, Gleiter CH, Eichelbaum M, Kivistö KT.

Clin Pharmacol Ther. 2005 Oct;78(4):378-87.

PMID:
16198657
13.

Disposition of oral and intravenous pravastatin in MRP2-deficient TR- rats.

Kivistö KT, Grisk O, Hofmann U, Meissner K, Möritz KU, Ritter C, Arnold KA, Lutjöohann D, von Bergmann K, Klöting I, Eichelbaum M, Kroemer HK.

Drug Metab Dispos. 2005 Nov;33(11):1593-6. Epub 2005 Aug 17.

PMID:
16107564
14.

Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.

Niemi M, Backman JT, Kajosaari LI, Leathart JB, Neuvonen M, Daly AK, Eichelbaum M, Kivistö KT, Neuvonen PJ.

Clin Pharmacol Ther. 2005 Jun;77(6):468-78.

PMID:
15961978
15.

CYP3A5 genotype is associated with diagnosis of hypertension in elderly patients: data from the DEBATE Study.

Kivistö KT, Niemi M, Schaeffeler E, Pitkälä K, Tilvis R, Fromm MF, Schwab M, Lang F, Eichelbaum M, Strandberg T.

Am J Pharmacogenomics. 2005;5(3):191-5.

PMID:
15952872
16.

Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17.

Niemi M, Neuvonen PJ, Hofmann U, Backman JT, Schwab M, Lütjohann D, von Bergmann K, Eichelbaum M, Kivistö KT.

Pharmacogenet Genomics. 2005 May;15(5):303-9.

PMID:
15864131
17.

Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1).

Niemi M, Kivistö KT, Hofmann U, Schwab M, Eichelbaum M, Fromm MF.

Br J Clin Pharmacol. 2005 May;59(5):602-4. No abstract available.

18.

Rhabdomyolysis in a patient receiving atorvastatin and fluconazole.

Kahri J, Valkonen M, Bäcklund T, Vuoristo M, Kivistö KT.

Eur J Clin Pharmacol. 2005 Feb;60(12):905-7. Epub 2004 Dec 30. No abstract available.

PMID:
15625612
19.

Functional interaction of intestinal CYP3A4 and P-glycoprotein.

Kivistö KT, Niemi M, Fromm MF.

Fundam Clin Pharmacol. 2004 Dec;18(6):621-6. Review.

PMID:
15548232
20.

Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice.

Kivistö KT, Zukunft J, Hofmann U, Niemi M, Rekersbrink S, Schneider S, Luippold G, Schwab M, Eichelbaum M, Fromm MF.

Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):124-30. Epub 2004 Jul 30.

PMID:
15322734
21.

Lipid-lowering response to statins is affected by CYP3A5 polymorphism.

Kivistö KT, Niemi M, Schaeffeler E, Pitkälä K, Tilvis R, Fromm MF, Schwab M, Eichelbaum M, Strandberg T.

Pharmacogenetics. 2004 Aug;14(8):523-5.

PMID:
15284534
22.

High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1).

Niemi M, Schaeffeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C, Backman JT, Kerb R, Schwab M, Neuvonen PJ, Eichelbaum M, Kivistö KT.

Pharmacogenetics. 2004 Jul;14(7):429-40.

PMID:
15226675
23.

Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens.

von Richter O, Burk O, Fromm MF, Thon KP, Eichelbaum M, Kivistö KT.

Clin Pharmacol Ther. 2004 Mar;75(3):172-83.

PMID:
15001968
24.

Differential expression and function of CYP2C isoforms in human intestine and liver.

Läpple F, von Richter O, Fromm MF, Richter T, Thon KP, Wisser H, Griese EU, Eichelbaum M, Kivistö KT.

Pharmacogenetics. 2003 Sep;13(9):565-75.

PMID:
12972955
25.

Pharmacokinetic interactions with rifampicin : clinical relevance.

Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivistö KT.

Clin Pharmacokinet. 2003;42(9):819-50. Review.

PMID:
12882588
26.

The efficacy of simvastatin is not influenced by CYP2D6 polymorphism.

Geisel J, Kivistö KT, Griese EU, Eichelbaum M.

Clin Pharmacol Ther. 2002 Nov;72(5):595-6. No abstract available.

PMID:
12426523
27.

Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole.

Raaska K, Niemi M, Neuvonen M, Neuvonen PJ, Kivistö KT.

Clin Pharmacol Ther. 2002 Oct;72(4):362-9.

PMID:
12386638
28.

Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes.

Niemi M, Cascorbi I, Timm R, Kroemer HK, Neuvonen PJ, Kivistö KT.

Clin Pharmacol Ther. 2002 Sep;72(3):326-32.

PMID:
12235454
29.
30.

Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride.

Niemi M, Neuvonen PJ, Kivistö KT.

Clin Pharmacol Ther. 2001 Nov;70(5):439-45.

PMID:
11719730
31.

Effect of methylprednisolone on CYP3A4-mediated drug metabolism in vivo.

Villikka K, Varis T, Backman JT, Neuvonen PJ, Kivistö KT.

Eur J Clin Pharmacol. 2001 Sep;57(6-7):457-60.

PMID:
11699609
32.

Stereoselective pharmacokinetics of cisapride in healthy volunteers and the effect of repeated administration of grapefruit juice.

Desta Z, Kivistö KT, Lilja JJ, Backman JT, Soukhova N, Neuvonen PJ, Flockhart DA.

Br J Clin Pharmacol. 2001 Oct;52(4):399-407.

33.

Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.

Wen X, Wang JS, Backman JT, Kivistö KT, Neuvonen PJ.

Drug Metab Dispos. 2001 Nov;29(11):1359-61.

PMID:
11602509
34.

Activated charcoal alone and followed by whole-bowel irrigation in preventing the absorption of sustained-release drugs.

Lapatto-Reiniluoto O, Kivistö KT, Neuvonen PJ.

Clin Pharmacol Ther. 2001 Sep;70(3):255-60.

PMID:
11557913
35.

The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.

Niemi M, Neuvonen PJ, Kivistö KT.

Clin Pharmacol Ther. 2001 Jul;70(1):58-65.

PMID:
11452245
36.

Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide.

Niemi M, Backman JT, Neuvonen M, Neuvonen PJ, Kivistö KT.

Clin Pharmacol Ther. 2001 Jun;69(6):400-6.

PMID:
11406737
37.

Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole.

Kivistö KT, Wang JS, Backman JT, Nyman L, Taavitsainen P, Anttila M, Neuvonen PJ.

Eur J Clin Pharmacol. 2001 Apr;57(1):37-42.

PMID:
11372588
38.

Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate.

Kyrklund C, Backman JT, Kivistö KT, Neuvonen M, Laitila J, Neuvonen PJ.

Clin Pharmacol Ther. 2001 May;69(5):340-5.

PMID:
11372002
39.

Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.

Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivistö KT.

Clin Pharmacol Ther. 2001 Apr;69(4):194-200.

PMID:
11309547
40.

Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations.

Kyrklund C, Backman JT, Kivistö KT, Neuvonen M, Laitila J, Neuvonen PJ.

Clin Pharmacol Ther. 2000 Dec;68(6):592-7.

PMID:
11180018
41.

Effects of metronidazole on midazolam metabolism in vitro and in vivo.

Wang JS, Backman JT, Kivistö KT, Neuvonen PJ.

Eur J Clin Pharmacol. 2000 Nov;56(8):555-9.

PMID:
11151744
42.

Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepiride.

Niemi M, Kivistö KT, Backman JT, Neuvonen PJ.

Br J Clin Pharmacol. 2000 Dec;50(6):591-5.

43.

Identification of drugs ingested in acute poisoning: correlation of patient history with drug analyses.

Pohjola-Sintonen S, Kivistö KT, Vuori E, Lapatto-Reiniluoto O, Tiula E, Neuvonen PJ.

Ther Drug Monit. 2000 Dec;22(6):749-52.

PMID:
11128245
44.

Rifampin decreases the plasma concentrations and effects of repaglinide.

Niemi M, Backman JT, Neuvonen M, Neuvonen PJ, Kivistö KT.

Clin Pharmacol Ther. 2000 Nov;68(5):495-500.

PMID:
11103752
45.
46.

Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin.

Lilja JJ, Kivistö KT, Neuvonen PJ.

Clin Pharmacol Ther. 2000 Oct;68(4):384-90.

PMID:
11061578
47.

Grapefruit juice can increase the plasma concentrations of oral methylprednisolone.

Varis T, Kivistö KT, Neuvonen PJ.

Eur J Clin Pharmacol. 2000 Sep;56(6-7):489-93.

PMID:
11049012
48.

Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1'-hydroxylation.

Palovaara S, Kivistö KT, Tapanainen P, Manninen P, Neuvonen PJ, Laine K.

Br J Clin Pharmacol. 2000 Oct;50(4):333-7.

49.

Effect of grapefruit juice dose on grapefruit juice-triazolam interaction: repeated consumption prolongs triazolam half-life.

Lilja JJ, Kivistö KT, Backman JT, Neuvonen PJ.

Eur J Clin Pharmacol. 2000 Aug;56(5):411-5.

PMID:
11009051
50.

Plasma concentrations of active simvastatin acid are increased by gemfibrozil.

Backman JT, Kyrklund C, Kivistö KT, Wang JS, Neuvonen PJ.

Clin Pharmacol Ther. 2000 Aug;68(2):122-9.

PMID:
10976543

Supplemental Content

Loading ...
Support Center